Canada markets close in 6 hours 21 minutes
  • S&P/TSX

    20,191.06
    +17.71 (+0.09%)
     
  • S&P 500

    4,398.36
    -3.10 (-0.07%)
     
  • DOW

    35,052.06
    -6.46 (-0.02%)
     
  • CAD/USD

    0.7942
    +0.0006 (+0.08%)
     
  • CRUDE OIL

    72.02
    +0.37 (+0.52%)
     
  • BTC-CAD

    49,880.43
    +973.10 (+1.99%)
     
  • CMC Crypto 200

    928.86
    -1.07 (-0.11%)
     
  • GOLD FUTURES

    1,796.60
    -3.20 (-0.18%)
     
  • RUSSELL 2000

    2,191.83
    -25.09 (-1.13%)
     
  • 10-Yr Bond

    1.2680
    +0.0340 (+2.76%)
     
  • NASDAQ

    14,671.53
    +10.95 (+0.07%)
     
  • VOLATILITY

    18.73
    +1.15 (+6.54%)
     
  • FTSE

    7,008.01
    +11.93 (+0.17%)
     
  • NIKKEI 225

    27,581.66
    -388.56 (-1.39%)
     
  • CAD/EUR

    0.6730
    +0.0019 (+0.28%)
     

Dendreon Pharmaceuticals Invests in Contract Manufacturing and Patient Services for Cell Therapy Partners

·2 min read

– Leader in the Commercial Delivery of Cell Therapies Offers Core Capabilities to Fill Expertise Gap in the Market –

SEAL BEACH, Calif., Jun 15, 2021--(BUSINESS WIRE)--Dendreon Pharmaceuticals, a commercial-stage biopharmaceutical company and pioneer in the development of cellular immunotherapy, has established and invested in its new contract manufacturing and services division to bring late-stage clinical assets through to commercialization. Leveraging its extensive manufacturing, process development and logistics expertise, Dendreon now offers end-to-end manufacturing of complex cell therapies and patient logistics for partner programs.

"Innovative cell therapies have the potential to change how we treat serious diseases, but there is currently insufficient capacity to meet anticipated industry demand," said Jason O’Neill, Chief Executive Officer of Dendreon. "With more than a decade of proven expertise in cell therapy manufacturing and an established supply chain and logistics infrastructure, we have invested in an offering that fills an immediate market need in this rapidly expanding field. This is a significant accomplishment for Dendreon and plays a key role in our future growth plans."

Dendreon is one of only four companies manufacturing cell therapies for commercial use in the United States and began investing in dedicated capacity for later-stage partner programs within its existing infrastructure in early 2021. The company’s 180,000+ square foot cGMP-compliant and FDA approved manufacturing facility in Seal Beach, CA will serve as the contract manufacturing services hub. Its Seattle facility will serve as the process development and manufacturing sciences center.

"We are enabling the future of immunotherapy and supporting an unmet need in the market with immediate access to capacity and expertise," said Maria Cho, Vice President of Business Development and Corporate Strategy. "We are looking to establish partnerships with biopharmaceutical companies developing CAR-Ts, autologous, or allogeneic cell therapies. Looking ahead, we plan to continue to leverage our core capabilities as a growth engine for our strategic partners and the industry as a whole."

For more information about Dendreon’s contract manufacturing services division, please visit https://www.dendreon.com/Partner-With-Us.

About Dendreon

Dendreon is a commercial-stage biopharmaceutical company and end-to-end provider of manufacturing services for the cell therapy market. Dendreon’s flagship product, PROVENGE® (sipuleucel-T), was the first FDA-approved immunotherapy made from a patient’s own immune cells and has been prescribed to over 40,000 men with advanced prostate cancer in the U.S. since 2010. Dendreon is headquartered in Seal Beach, Calif. For more information, please visit www.dendreon.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210615005281/en/

Contacts

Annalisa Ledonne
annalisa.ledonne@Dendreon.com
T +1.857.939.1991

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting